SWOG Myeloma Trial Therapy Lengthens
Time Before Reoccurrence and Life
At the 57th annual meeting of ASH, the American Society of Hematology, on Dec. 5, SWOG presented exciting results from the S0777 clinical trial on myeloma that may indicate a new standard of care for this disease.
S0777 is a Phase III clinical trial in front-line Multiple Myeloma which enrolled 471 eligible and analyzable adult patients, ages 28 to 87, between February 2008 and February 2012 at institutions of the National Cancer Institute National Cancer Trials Network. Patients were randomized to two treatment groups. One group received standard first-line treatment of lenalidomide and dexamethasone while the other group received lenalidomide and dexamethasone combined with bortezomib, a drug that is typically given as a second-line therapy to patients whose cancer progresses. At ASH, SWOG researchers revealed that patients in the three drug arm that included bortezomib had a median remission time of 43 months compared to 30 months in the two drug arm and lived a median of 75 months compared to 64 months in the arm with only lenalidomide and dexamethasone.
CRAB contributed to this trial with statistical, data management, and technology support as a member of the SWOG Statistical and Data Management Center housed at the Fred Hutchinson Cancer Research Center and CRAB.
For more information on the results, please read SWOG’s press release here: http://swog.org/Visitors/Download/Media/S0777PressRelease.pdf.